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Summary 
 
We explored associations between all-cause-death-rate (DR), cardiac radiation doses and 
electrocardiographic (ECG) changes in 78 patients with locally advanced non-small cell lung 
cancer treated in IDEAL-CRT, a trial of isotoxically-escalated concurrent chemoradiation. We 
found evidence of associations between higher DR and conduction or ischaemic/pericarditis-like 
changes on ECG at 6 months, and between higher DR and higher heart or left atrial wall volumes 
receiving 63-69Gy. 
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The impact of cardiac radiation dosimetry on survival following  
radiotherapy for non-small cell lung cancer  
Abstract 
Purpose: The heart receives high radiation doses during radiotherapy of advanced-stage lung 
cancer. We have explored associations between overall survival, cardiac radiation doses and 
electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically-
escalated concurrent chemoradiation delivering tumor doses of 63-73Gy. 
Patients and Methods: Dosimetric and survival data were analyzed for 78 patients. The whole 
heart, pericardium, AV node, and walls of left and right atria (LA/RA-Wall) and ventricles 
(LV/RV-Wall) were outlined on radiotherapy planning scans, and differential dose-volume-
histograms (dDVHs) were calculated. For each structure, dDVHs were approximated using the 
average dDVH and the 10 highest ranked structure-specific principal components (PCs). ECGs 
at baseline and 6 months post-radiotherapy were analyzed for 53 patients, dichotomizing patients 
according to presence or absence of ‘any ECG change’ (conduction or ischemic/pericarditis-like 
change). All-cause death-rate (DR) was analyzed from the start of treatment using Cox 
regression. 
Results: 38% had ECG changes at 6 months. On univariable analysis, higher scores for LA-
Wall-PC6, Heart-PC6, ‘any ECG change’ and larger planning target volume (PTV) were 
significantly associated with higher DR (p = .003, .009, .029 and .037 respectively). Heart-PC6 
and LA-Wall-PC6 represent larger volumes of whole heart and left atrial wall receiving 63-
69Gy. Cardiac doses ≥63Gy were concentrated in the LA-wall and consequently Heart-PC6 was 
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highly correlated with LA-Wall-PC6. ‘Any ECG change’, LA-Wall-PC6 scores and PTV size 
were retained in the multivariable model. 
Conclusion: We found associations between higher DR and conduction or ischemic/pericarditis-
like changes on ECG at 6 months, and between higher DR and higher Heart-PC6 or LA-Wall-
PC6 scores, which are closely related to heart or left atrial wall volumes receiving 63-69Gy in 
this small cohort of patients.  
 
Introduction 
 
Definitive chemo-radiation (CRT) is the standard of care for locally-advanced non-small cell 
lung cancer (NSCLC).1 For more than 30 years the accepted radiotherapy dose was 60–63Gy in 
1.8–2.0Gy fractions, established by Radiation Therapy Oncology Group trial RTOG-7301.2,3 
Overall survival (OS) is poor at these dose-levels, with high local failure rates stimulating 
interest in dose-escalation. Outcomes modelling suggests a tumor dose-response,4 and results 
from early-phase studies indicated that concurrent CRT might be safe up to 74Gy.5-12 However 
the RTOG-0617 phase III trial of dose-escalation has reported a significantly lower OS for 74Gy 
than for 60Gy in daily 2Gy fractions, triggering efforts to identify reasons for the reduced 
survival.13 An RTOG-0617 analysis found negative associations between OS and high heart 
volumes receiving more than 5Gy or 40Gy.13,14 A recent meta-analysis of randomised trials in 
NSCLC found that for concurrent chemoradiation treatments, higher radiation doses result in 
poorer OS, possibly partly due to higher levels of toxicity in the presence of concurrent 
chemotherapy.15 
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Radiation induced heart disease (RIHD) has been associated with poorer long-term OS in breast 
and lymphoma survivors.16,17 For locally-advanced NSCLC patients the impact of cardiac 
irradiation on OS has not been well-characterized, because RIHD latency was thought to be 
longer than the typical OS. However NSCLC patients are generally older than breast cancer or 
lymphoma patients, have more underlying cardiopulmonary conditions and common risk factors 
for ischemic heart disease, and receive higher target radiation doses. Interest in R HD following 
NSCLC radiotherapy has therefore increased as evidence has emerged suggesting that RIHD 
impacts OS earlier than previously thought.18,19   
In this post-hoc analysis of the prospective data from IDEAL-CRT20, we aim to identify the 
impact of cardiac irradiation on the all-cause death-rate (DR) using a dose volume histogram-
wide analysis approach based on principal components analysis (PCA). We further attempt to 
localize to specific cardiac substructures the associations seen between whole-heart dosimetry 
and DR, since in clinical practice whole heart avoidance may not be feasible. To explore 
pathophysiological connections between cardiac irradiation and survival we evaluate 
electrocardiogram (ECG) changes after irradiation. 
 
Materials and methods 
 
Population  
Data were analyzed for 78 of all 82 stage IIB/III NSCLC patients recruited and treated in 
IDEAL-CRT, a phase I/II trial of isotoxically-escalated CRT which delivered 63-73Gy in 30 
fractions over 6 weeks, concurrently with 2 cycles of Vinorelbine and Cisplatin.  Four patients 
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were excluded, one due to corrupted radiotherapy planning archival records, two to re-planning 
during treatment, and one to treatment termination following toxicity after five fractions 
resulting in very low heart doses. 
 
ECG scoring 
ECGs obtained at baseline and 6 months after CRT were assessed by two cardiologists (SR and 
AK) in a blinded manner for the following characteristics: normal ECG; new rhythm changes 
compared to baseline (sinus tachycardia/bradycardia, conduction abnormalities such as bundle 
branch block, atrial fibrillation); and ischemic or pericarditis-like changes (new or worsening ST 
and T wave changes compared to baseline). ECG changes between the two time-points were then 
scored dichotomously as present or absent (‘any ECG change’). 
 
Processing of radiotherapy dosimetric data 
Treatment plans were imported into the open-source Computational Environment for 
Radiotherapy Research (CERR) software written in MATLAB R2012b (The Mathworks, Inc., 
Natick, MA; http:\\www.mathworks.com). Whole-heart contours delineated by physicians at 
participating centres were checked by DL and SV. The pericardium, right atrium (RA), right 
ventricle (RV), left atrium (LA), left ventricle (LV) and AV node (AVN) were delineated as 
individual substructures by SV using a modified version of a validated cardiac atlas.21 The 
pericardium was defined as a rim volume lying 5mm or less beyond the heart, and the outlined 
AVN was expanded by 3mm superiorly-inferiorly to account for delineation variability. RA-
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Wall, RV-Wall, LA-Wall and LV-Wall were defined as wall regions lying 5mm or less within 
the RA, RV, LA and LV contours. 
 
Differential dose-volume-histograms (dDVH) with 1Gy dose-bins were constructed for the 
whole heart and all substructures, and exported to SPSS.23 (IBM Corp., Armonk, NY) and 
R3.2.3 (R Foundation, Vienna, Austria) for further processing. Separate principal components 
analyses (PCA) were carried out for the whole heart and each cardiac substructure, representing 
patients’ dDVHs as linear sums of structure-specific orthogonal principal components (PCs) and 
the population-averaged dDVH (Appendix A).22-26 The scores of the PCs in these linear sums 
reflect the degrees to which they are present in each patient’s dDVH. For each cardiac structure, 
PCA allowed the highly-correlated dose-distributions of the whole patient group to be efficiently 
approximated by a truncated set of PCs, specifically the 10 highest-ranked PCs obtained from 
PCA for that specific structure. Scores of the initially-obtained PCs were uncorrelated across the 
patient group, each PC describing a unique and independent portion of the dosimetric variability. 
However, these PCs contained numerous peaks, obscuring their physical interpretation. We 
therefore used varimax rotation to simplify the PC structure,27 applying an orthogonal rotation to 
the truncated set of PCs. The rotated PCs are more easily interpretable, mostly having non-
negligible amplitudes across only narrow dose regions, although their scores are no longer 
orthogonal. 
 
Statistical analysis 
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Univariable and multivariable analyses (UVA/MVA) of hazard ratios (HRs) for the all-cause 
death-rate (DR) (measured from the start of treatment) were performed using Cox proportional 
hazards regression. Factors analyzed for association with DR were: clinical (patient and 
treatment) characteristics, ECG changes, and scores of the 10 highest-ranked whole-heart 
dosimetry PCs. Relevant clinical factors, ECG changes, and PCs having p-values ≤.20 on UVA 
were initially included in multivariable models, and stepwise bi-directional variable elimination28 
was performed to find the model with the lowest Akaike Information Criterion (AIC) score.29 
 
The false-discovery-rate for significant associations following multiple hypothesis testing was 
controlled using the Benjamini-Hochberg step-up procedure to identify positive discoveries 
(Appendix-B). The predictive abilities of multivariable models were characterized using 
Harrell's-Concordance(C)-statistic.30,31 The C-statistic of a model is 1.0 if for all possible pairs of 
patients, it correctly predicts which patient has the longer survival. A value of 0.5 indicates a 
model performance no better than chance.  
 
Associations between dichotomized ECG changes and the scores of PCs significantly associated 
with DR on MVA were tested using logistic regression. 
 
Two approaches were used to further localize the associations seen between DR and whole-heart 
dosimetry to specific cardiac substructures. The first involved UVA/MVA of associations 
between DR and the scores of individual cardiac substructure PCs (ss-PCs). To avoid excessive 
multiple testing we only studied ss-PCs closely aligned with ‘heart-PCmax’, the whole-heart PC 
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most strongly associated with DR, using a normalized dot product (NDP) criterion described in 
Appendix-C to assess closeness of alignment. 
 
The second approach was a graphical interrogation of the shapes of the heart dose-distributions 
of all 78 patients, mapped to a single reference geometry using an in-house MATLAB program 
(described in detail in Appendix D). Binary masks were created from each patient's whole heart 
and left and right atria and ventricles, and registered to the corresponding masks of a reference 
patient by affine transformation. 3D dose distributions were mapped to the reference geometry 
via the same affine transformations, and a threshold was applied to identify the region where 
dose was associated with the peak in heart-PCmax (as quantified in the Results section) for each 
patient. These high-dose regions were visualized by taking 2D projections through the reference 
geometry in each principal anatomical plane (transverse, coronal, sagittal), producing images 
with pixel values that represent the percentage of patients for whom the projected high-dose 
region is present at each point in the plane. Projections were convolved with a Gaussian 
smoothing kernel (3mm standard deviation) to avoid identification of features smaller than the 
typical registration error. This process was carried out for both for the whole heart and for each 
cardiac substructure, allowing visual localization of the high-dose peak. 
 
Results 
 
Population, ECG and radiotherapy dosimetry data 
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Patient and treatment data are detailed in Table-1. ECG changes are also summarized in the 
Table, together with whole-heart and cardiac substructure dosimetry. 53 patients had analyzable 
ECGs at both baseline and 6 months post-radiotherapy, and 20 patients (38%) had documented 
changes. The mean whole-heart dDVH is plotted in Figure-1, alongside the 10 varimax-rotated 
whole-heart PCs which described more than 95% of total variance.  
 
Associations between OS, clinical characteristics, ECG changes and whole-heart dosimetry 
Results from UVA are shown in Table-2. Patients with larger planning target volumes (PTVs) or 
‘any ECG change’ had significantly higher HRs for DR (p=.04 and .03 respectively). However 
when analyzed separately, ischemic/pericarditis-like ECG changes and conduction ECG changes 
were not statistically significantly associated with DR. The presence of an abnormal baseline 
ECG was not significantly associated with DR (Table 2), or with onset of any ECG change at 6 
months after treatment. 
 
Higher DR was significantly associated with larger Heart-PC6 scores (p=.009) (Table-2). Heart-
PC6 has a prominent peak at 63-69Gy and a dip at 0-4Gy (Figure-1), and therefore in patients 
with high Heart-PC6 scores, heart volumes receiving 63-69Gy (VHeart-63-69) and 0-4Gy (VHeart-0-4) 
are respectively relatively large and small. Higher DR is more plausibly linked to larger volumes 
receiving high doses than to smaller volumes receiving low doses, an interpretation supported by 
a significant association found between VHeart-63-69  and DR (HR=1.13, p=.03) but not between 
VHeart-0-4 and DR (HR=1.002, p=.76). Heart-PC6 was not significantly correlated with PTV size 
(Pearson correlation r=.21; p=.06) or with prescribed dose (r=.08; p=.51). (Appendix E) 
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Significant correlations between DR and PTV size, ‘any ECG change’, and Heart-PC6 remained 
classified as positive discoveries when the false-discovery-rate (FDR) was limited to 20% via the 
Benjamini-Hochberg procedure. The multivariable model judged best according to the AIC 
retained Heart-PC6 (p=.02), ‘any ECG change’ (p=.04) and PTV size (p=.08) as factors 
associated with DR (Table-3), and had a good Harrell’s-C-statistic of 0.76.32 
 
Associations between cardiac substructure dosimetry and OS  
The hearts of 62 patients received doses in excess of 63Gy (the lower end of the peak of Heart 
PC6), and in 82% of these patients ≥1cm3 of heart received ≥63Gy. High dose-levels were 
concentrated in the left atrium and overlying pericardium (Figure-2): specifically, doses ≥63Gy 
were delivered to the pericardium in all 62 patients, to LA-Wall in 48 (77%), RA-Wall in 22 
(36%), LV-Wall in 18 (29%), RV-Wall in 16 (26%) and AVN in 2 (3%) patients. In the 20 
patients with top quartile Heart-PC6 scores, the median heart and LA-wall fractional volumes 
receiving ≥63Gy (VHeart63, VLA-wall63) were 4% (range 1-18%) and 16% (2-77%) respectively, 
compared to 0.3% (0-14%) and 0% (0-22%) in the other 58 patients. 
 
LA-Wall-PC6 and Pericardium-PC5 were the only substructure PCs with NDPs >1 (Appendix-
C). Like Heart-PC6, they both had prominent 63-69Gy peaks (Figure-1), and their scores were 
highly correlated with those of Heart-PC6 (p <0.01, Spearman correlation coefficients of r=.81 
and .91 respectively). LA-Wall-PC6 and Pericardium-PC5 scores were both significantly 
associated with DR on UVA (Table-2), and these associations remained classified as positive 
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discoveries when the Benjamini-Hochberg procedure was used to limit the FDR to 20%, 
alongside the associations between DR and PTV size, ‘any ECG change’ and Heart-PC6 score.  
 
In MVA of all factors including both whole-heart and substructure dosimetry, the model judged 
best according to the AIC retained higher LA-Wall-PC6 score (p=.02), presence of ‘any ECG 
change’ (p=.07) and PTV size (p=.10) as factors associated with higher DR, the LA-Wall-PC6 
score superseding Heart-PC6 (Table-3). This model’s Harrell’s-C-statistic was good at 0.75. 
 
Scale of OS variation with heart dosimetry and ECG changes 
Tables-2 and -3 list DR hazard ratios (HRs) for the factors studied on UVA and MVA. The scale 
of association between VLA-Wall-63 and DR can be seen in survival curves plotted in Figure-3: for 
patients with VLA-Wall-63 values below or above the median level of 2.2%, median OS was 39.2 
and 27.9 months respectively. At 24 months post-treatment survival was 23% higher (81% vs 
58%) for patients with less highly irradiated atrial wall volumes. The scale of association 
between DR and ECG changes is shown in the survival curves split by the presence or absence 
of any ECG change, also plotted in Figure-3. 
 
Correlations between ECG changes and dosimetry  
Correlations between ‘Any ECG change’ and scores for Heart-PC6, Pericardium-PC5 and LA-
Wall-PC6 were not significant (p=.90, .77 and .44 respectively). (Appendix-G) 
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Discussion 
 
To our knowledge this is the first study to use a DVH-wide analysis based on principal 
components to explore associations between heart irradiation and death-rate in NSCLC patients, 
rather than using discrete dose-volume point metrics. It is also the first to analyze ECG changes 
and detailed cardiac substructure dosimetry in relation to DR in these patients. 
 
We have found higher DR to be significantly associated with the presence of ‘any ECG change’ 
6 months after radiotherapy, and with large PTV size and larger values of VHeart-63-69, the whole-
heart volume receiving 63-69Gy. Cardiac doses of 63-69Gy were concentrated in the left atrium 
and overlying pericardium, and correspond to 64-73Gy equivalent dose in 2Gy fractions (EQD2) 
for α/β = 3Gy. The scale of associations between DR and heart and substructure volumes 
receiving 63Gy was substantial, despite median values of these volumes being low (2, 5 and 8% 
for whole-heart, pericardium and LA-Wall respectively). Since VHeart-63-69 was not significantly 
correlated with PTV size or prescribed dose, the association between heart dose and DR is likely 
independent of these latter two factors; indeed, both PTV size and Heart-PC6 are retained in the 
whole-heart multivariable model judged best by the AIC criterion, while prescribed dose is not 
significantly correlated with DR on univariable analysis. 
 
We have additionally explored the impact on DR of the presence of N2/3 disease, and of 
subcarinal nodal involvement (Appendix H). On univariable analysis neither N2/3 disease nor 
involvement of subcarinal nodes was significantly associated with DR (p = 0.42 and 0.12 
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respectively). After adding these factors into the multivariable models of Table 3, heart and left 
atrial wall PC6 remained significantly associated with DR (p=0.03, with very slightly reduced 
HRs), while subcarinal nodal involvement was also retained in the multivariable model judged 
best on AIC (p=0.07). In this dataset, then, there is no indication that nodal N2/3 disease or 
subcarinal nodal involvement were confounders of the observed associations between cardiac 
dosimetry and DR.      
 
Due to the proximity of the heart to lung tumors and nodes, it is difficult to avoid the entire heart 
when escalating tumor dose. It would therefore be useful to identify specific radiosensitive 
cardiac substructures to spare preferentially, but little data exist regarding cardiac substructure 
dosimetry. Although irradiation of the left atrial wall was significantly associated with DR in our 
study, it was not possible to determine whether this was because damage to this structure was 
particularly critical, or whether the association simply reflects the strong correlation between 
whole-heart and left atrial volumes receiving 63-69Gy (Spearman correlation r=0.88, p<0.01). 
 
A recent review found no consensus on heart dose-constraints used in NSCLC treatments, with 
most studies setting very lenient constraints especially at higher heart dose-levels.33  In IDEAL-
CRT upper limits of 60, 53 and 45Gy were placed on D33%, D67%, D100% respectively, the lowest 
doses delivered to the most highly-irradiated 33%, 67% and 100% of the heart.20  One study set a 
strict maximum heart dose-limit of 63Gy34, and in light of the associations we have seen between 
DR and VHeart63-69 we are presently investigating whether this limit can be met while delivering 
the 63-73Gy IDEAL-CRT range of prescribed doses. The lack of well-defined heart constraints 
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reflects the scarcity of studies exploring the dose-dependence of RIHD following radiotherapy 
for NSCLC. 
 
Our results provide direct evidence that DR is associated with cardiac irradiation following 
radiotherapy for NSCLC. This adds to existing indirect evidence from the Post-Operative 
Radiotherapy (PORT) meta-analysis, which demonstrated a 7% absolute reduction in 2-year OS 
and higher rates of non-cancer-related deaths for irradiated compared to non-irradiated NSCLC 
patients.35 Analysis of the SEER database found this increased risk of death existed in patients 
treated with PORT between 1983 and 1988, but not between 1989 and 1993, possibly due to 
better normal tissue sparing following the introduction of conformal radiotherapy and higher-
energy linear accelerators rather than Cobalt machines.36 Greater heart toxicity and mortality 
rates have also been reported for NSCLC patients with irradiated left- rather than right-sided 
tumors.36,37 Studies have found negative associations between OS and non-radiotherapy-related 
cardiac morbidity in NSCLC patients, suggesting that the additive effect of RIHD has the 
potential to further worsen OS.38,39   
 
Radiation-induced fibrosis is thought to be a key mechanism in the development of cardiac 
dysfunction following radiotherapy. In rats, fibrosis accumulation and dose-dependent decreases 
in end-diastolic diameter were seen one month after single fractions of 15 or 20Gy, and deaths 
due to cardiac failure occurred after 22.5Gy.40,41 The impact of atrial irradiation on survival was 
demonstrated by the higher survival seen when atria were specifically spared during heart 
irradiation.40 
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Atrial fibrosis is commonly seen in patients with atrial fibrillation (AF) and plays an important 
role in the pathophysiology of AF.42-45 Continuous AF can lead to LV dysfunction, increased LA 
pressure and impaired atrial contractility, and has been associated with worse clinical outcomes 
including stroke.46 A surrogate for fibrosis, late gadolinium enhancement (LGE) on MRI, has 
been seen in the left atrial walls of patients with AF. In patients with esophageal cancer LGE has 
been seen in areas of heart receiving 40Gy, and more so in regions receiving 60Gy, however it is 
not seen outside radiation fields.47 This dose-effect is supported by evidence from an esophageal 
cancer study which found microvasculature circulation obstruction in 0%, 43% and 68% of 
myocardial segments receiving 0, 40 and 60Gy respectively.48,49 In another study, 14% of 
esophageal cancer patients had symptomatic cardiac disease at 5 years after radiotherapy, the risk 
varying with the fractions of whole-heart volumes receiving ≥45, 50 and 55Gy.50 In summary, 
imaging studies have demonstrated radiation dose-related cardiac changes in patients, but further 
work is required to directly associate these changes with morbidity and mortality. 
 
Some limitations of our study must be acknowledged. Firstly, although a prospective study, our 
analysis was post-hoc and lacked comorbidity or smoking status data, which may be additive risk 
factors for RIHD.  Secondly, the resting 12-lead-ECG has limited value as an indicator of subtle 
pathological changes within the heart.51,52 However, in a similar population over the age of 65 
without lung malignancies but with baseline ECG changes, the rate of non-fatal and fatal 
cardiovascular events at 6 months was only around 2%.53 Thus the higher rate of ECG changes 
(38%) observed at 6 months in this study is likely due to the effect of radiotherapy.  
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Thirdly, the study is relatively small, and its findings must consequently be interpreted with 
caution. Although we found DR to be associated with dosimetry and ECG changes, we could not 
distinguish truly cardiac-related deaths from cancer-related deaths, as there was a lack of cardiac-
specific morbidity or mortality data, and all patients with early death had tumor relapse. 
Recording of cause-of-death is complicated, since deaths of radiotherapy patients following 
cardiac arrest could be scored as cancer-related.  
 
Fourthly, although we found an association between high doses to left atrium and poorer 
survival, the mechanism remains unclear. Although we used a validated atlas21 to define the 
cardiac substructure, there remains some uncertainty in our substructure outlines due to motion. 
Finally, while PCA provides a very efficient way of reducing many highly correlated dosimetric 
variables to a few factors, the clinical interpretation of the resulting varimax-rotated PCs can be 
challenging. 
 
Conclusion 
 
In this small cohort of NSCLC patients we have seen significant associations between all-cause 
death-rate and higher heart volumes receiving 63-69Gy (particularly the left atrial wall). The 
observed associations suggest that small volumes of heart receiving high radiation doses may 
have a negative impact on survival, greater and more acute than that seen in breast cancer and 
lymphoma patients who are treated using lower radiation doses. Our study is hypothesis-
generating, and requires further work to establish a causal relationship between RT and 
mortality. The pathophysiology of acute RIHD needs to be determined in prospective functional 
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imaging studies before we recommend modification of treatment plans on the basis of these 
initial results, for example, to reduce heart doses receiving ≥63Gy, particularly if this 
compromises dosimetric PTV coverage. Our finding of an association between DR and ECG 
changes at 6 months after treatment does, however, tentatively suggest a link between DR and 
RT-induced cardiac damage. 
Given the armoury of intensity-modulated photon and ion beam radiotherapy technology 
available, outcomes of dose-escalated NSCLC treatments may be improvable in future via 
cardiac-sparing dose-escalation techniques, given greater knowledge of links between survival, 
cardiac pathophysiology, and whole-heart and substructure dosimetry. 
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Tables and Figure captions 
Table 1. Treatment, ECG and radiation dosimetry data for 78 patients analyzed.  
$
 Performance status 0 - able to carry out all normal activity without restriction. 
  Performance status 1 - restricted in strenuous activity but ambulatory and able to carry out light 
work. 
* EQD2: equivalent dose in 2 Gy fractions, calculated for / = 3 Gy. 
 
Table 2. Univariable Cox proportional hazards regression models of all-cause death-rate versus 
(a) clinical factors, (b) whole heart dosimetry PCs, (c) cardiac substructure dosimetry PCs. Data 
from 78 patients were analyzed for all factors except ECG change, for which paired data was 
available for 53 patients. (p-values are uncorrected for multiple-hypothesis testing). 
 
Table 3. Multivariable Cox proportional hazards models of all-cause death-rate judged best 
according to the AIC measure. Factors initially included in the modelling were: * clinical 
characteristics of Table 2 and whole-heart PCs with p-value <0.2 on UVA (PC2, PC6, PC9); and 
$
 substructure PCs with p-value <0.2 on UVA (Pericardium-PC5, Left atrial Wall-PC6)  
(p-values are uncorrected for multiple-hypothesis testing). 
 
Figure 1. The mean whole-heart dDVH of 78 patients, plotted together with the 10 varimax-
rotated principal components (PCs) describing >95% of the whole-heart dosimetric variance, and 
Left atrial wall PC-6 (LA-Wall-PC6) and Pericardium-PC5 (Peri-PC5). For ease of visualization, 
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the loadings (fractional volumes receiving different dose-levels) of the PCs have been scaled so 
that for each PC the maximum absolute value is one. 
 
Figure 2. Three perspective views of the reference whole-heart geometry, and the left/right atria 
(LA/RA) and ventricles (LV/RV) plotted separately. The colourwash indicates percentages of 
patients whose heart dose-distributions, mapped to the reference geometry, have values ≥63Gy 
somewhere along lines perpendicular to the image plane. Data are shown for the 51 patients with 
VHeart63>1cm3 (left) and the 20 patients with the highest Heart-PC6 scores (right). 
 
Figure 3. Kaplan-Meier overall survival (OS) curves for patients dichotomized by: (left) volume 
of Left atrial wall receiving greater than 63Gy (VLA-Wall63) being greater than/equal to or lesser 
than 2.2% (its median value) (78 patients, 26 events); (right) No ECG change vs ECG change at 
6 months post-treatment (53 patients, 18 events). 
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Table 1. 
            Characteristic   
Age (years; median (range)) 66    (43-84) 
WHO performance status$ No.   (%) 
     0 32     (41.0) 
     1 46     (59.0) 
Gender  No.   (%) 
     Female 20     (25.6) 
     Male 58     (74.4) 
Stage  No.    (%) 
    IIB 6        (7.7) 
    IIIA  54      (69.2) 
    IIIB 18      (23.1) 
Nodal status  No.    (%) 
    N 2 or 3 65      (83.3) 
    N 0 or 1 13      (16.7) 
Histology  No.    (%) 
    Squamous 42      (53.8) 
    Non-squamous 36      (46.2) 
Planning target volume (PTV) (cm3; median (range)) 400.6 (138.7-1262.1) 
Analyzable ECGs No.     (%) 
    Baseline 71       (91.0) 
    6 months 56       (71.8) 
    Baseline and 6 months 53       (67.9) 
Normal ECGs (time-point)  No.     (%) 
    Baseline 38       (48.7) 
    6 months 18       (23.1) 
ECG changes from baseline to 6 months No.     (%) 
    Rhythm change 9         (11.5) 
    Ischemic or pericarditis-like change 11       (14.1) 
Prescribed dose (Gy; median (range)) 67.6    (63-73) 
Mean EQD2*  Gy; median (range) 
    Lung 14.7    (7.9-21.2) 
    Heart 8.0      (0.4-29.2) 
    Left atrium wall 17.1    (0.5-64.2) 
    Left ventricle wall 2.8      (0.3-26.9) 
    Right atrium wall 4.3      (0.3-61.3) 
    Right ventricle wall 3.8      (0.3-29.0) 
    Atrioventricular node 2.2      (0.3-52.5) 
    Pericardium 10.8    (0.4-27.0) 
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Table 2. 
 
Co-variate 
 
p-value 
Hazard ratio  
(95% confidence 
interval) 
(a) Clinical factors  
  
Baseline abnormal ECG .96 0.98 (0.45-2.15) 
Any ECG change at 6 months .03 2.94 (1.12-7.76) 
PTV size (cm3) .04 1.002 (1.000-1.003) 
Prescribed dose (Gy) .25 0.93 (0.83-1.05) 
Performance status (0 vs 1) .35 1.49 (0.64-3.47) 
Nodal stage (0/1 vs 2/3) .42 1.64 (0.49-5.49) 
Age (years) .60 1.01 (0.97-1.06) 
Stage (IIba/IIIa vs IIIb) .80 1.13 (0.45-2.83) 
Gender (female vs male) .82 1.11 (0.44-2.79) 
Non-Squamous vs squamous .94 1.03 (0.47-2.27) 
(b) Whole heart dosimetry  
  
Heart-PC1  .28 1.18 (0.88-1.58) 
Heart-PC2  .12 0.52 (0.23-1.19) 
Heart-PC3  .56 0.83 (0.44-1.56) 
Heart-PC4  .77 0.94 (0.62-1.43) 
Heart-PC5  .48 1.15 (0.78-1.70) 
Heart-PC6  .01 1.54 (1.12-2.13) 
Heart-PC7  .78 1.05 (0.73-1.52) 
Heart-PC8  .60 1.11 (0.75-1.63) 
Heart-PC9  .16 0.73 (0.47-1.13) 
Heart-PC10 .65 0.92 (0.64-1.31) 
(c) Substructure dosimetry 
  
Left atrial Wall-PC6  .003 1.49 (1.14-1.95) 
Pericardium-PC5  .005 1.64 (1.16-2.33) 
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Table 3. 
 
Multivariable modelling including whole heart dosimetry*  
( Harrell’s-C-statistic: 0.76) 
Variables p-value Hazard ratio  (95% confidence interval) 
Heart-PC6 .02 1.58 (1.08-2.33) 
Any ECG change at 6 months .04 2.79 (1.03-7.50) 
PTV size (cm3) .08 1.00 (1.00-1.01) 
 
Multivariable modelling including whole heart and substructure dosimetry$   
(Harrell’s-C-statistic: 0.75) 
Variables p-value Hazard ratio  (95% confidence interval) 
Left atrial Wall-PC6 .02 1.52 (1.07-2.17) 
Any ECG change at 6 months .07 2.50 (0.92-6.81) 
PTV size (cm3) .10 1.00 (1.00-1.01) 
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